

Filippo de Braud

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7230534/filippo-de-braud-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

445
papers

21,420
citations

68
h-index

134
g-index

464
ext. papers

25,502
ext. citations

5.7
avg, IF

6.32
L-index

#	Paper	IF	Citations
445	Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study.. <i>Oncologist</i> , 2022 , 27, e29-e36	5.7	0
444	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102583	2.2	4
443	Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model.. <i>Frontiers in Oncology</i> , 2022 , 12, 857515	5.3	0
442	Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma. <i>Tumori</i> , 2021 , 107, 542-549	1.7	1
441	Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). <i>Expert Review of Anticancer Therapy</i> , 2021 , 1-7	3.5	2
440	Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211006960	5.4	1
439	Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 169, 103532	7	0
438	Fasting-mimicking diet is safe and reshapes metabolism and antitumor immunity in cancer patients. <i>Cancer Discovery</i> , 2021 ,	24.4	15
437	Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab □ Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 3926-3935	12.9	19
436	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic Fusion-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1253-1263	2.2	22
435	Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 160, 103299	7	3
434	EGFR Amplification in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1561-1569	9.7	3
433	Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors 2021 , 9,		5
432	Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9065-9065	2.2	2
431	A phase II study evaluating the efficacy of enzalutamide and the role of ARv7 in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with visceral disease.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5052-5052	2.2	
430	Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): The phase II LOLA trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS4167-TPS4167	2.2	
429	Response to selpercatinib versus prior systemic therapy in patients (pts) with RET fusion+ non-small-cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9032-9032	2.2	0

428	Recent Advances in the Management of Typical and Atypical Lung Carcinoids. <i>Clinical Lung Cancer</i> , 2021 , 22, 161-169	4.9	3
427	A phase 2 prospective trial of cabozantinib as first-line treatment for metastatic collecting ducts renal cell carcinoma: The BONSAI trial (Meeturo 2) clinical trial information NCT03354884.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4571-4571	2.2	2
426	The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021 , 150, 155-167	7.5	15
425	The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy. <i>Targeted Oncology</i> , 2021 , 16, 529-536	5	9
424	Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. <i>Clinical and Translational Medicine</i> , 2021 , 11, e434	5.7	2
423	Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer. <i>Cancer Letters</i> , 2021 , 511, 77-87	9.9	7
422	Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021 , 144, 31-40	7.5	5
421	Radical metastasectomy followed by sorafenib versus observation in patients with clear cell renal cell carcinoma: extended follow-up of efficacy results from the randomized phase II RESORT trial. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 261-268	3.8	1
420	Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence. <i>TH Open</i> , 2021 , 5, e56-e65	2.7	5
419	Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients 2021 , 9,		4
418	Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. <i>Lung Cancer</i> , 2021 , 152, 165-173	5.9	11
417	Thrombin generation predicts early recurrence in breast cancer patients. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2220-2231	15.4	6
416	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. <i>European Journal of Cancer</i> , 2020 , 135, 78-88	7.5	5
415	Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes. <i>Cancer Treatment Reviews</i> , 2020 , 88, 102057	14.4	13
414	A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors. <i>Cancers</i> , 2020 , 12,	6.6	2
413	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet</i>	21.7	98
412	Rapid Antibody Testing for SARS-CoV-2 in Asymptomatic and Paucisymptomatic Healthcare Professionals in Hematology and Oncology Units Identifies Undiagnosed Infections. <i>HemaSphere</i> , 2020 , 4, e408	0.3	5
411	Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. <i>European Journal of Cancer</i> , 2020 , 135, 230-239	7.5	6

410	COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: the COVINT study. <i>ESMO Open</i> , 2020 , 5,	6	9
409	Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 1017-1024	12.9	8
408	Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair deficient (dMMR) GI cancers.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 218-218	2.2	3
407	mutations confer poor prognosis in malignant pleural mesothelioma. <i>Translational Lung Cancer Research</i> , 2020 , 9, 1940-1951	4.4	
406	SMO mutations confer poor prognosis in malignant pleural mesothelioma. <i>Translational Lung Cancer Research</i> , 2020 , 9, 1940-1951	4.4	0
405	DHA Affects Microtubule Dynamics Through Reduction of Phospho-TCTP Levels and Enhances the Antiproliferative Effect of T-DM1 in Trastuzumab-Resistant HER2-Positive Breast Cancer Cell Lines. <i>Cells</i> , 2020 , 9,	7.9	4
404	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 156-164	3.8	12
403	A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer. <i>International Journal of Cancer</i> , 2020 , 146, 3495-3503	7.5	10
402	Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. <i>Lancet Oncology, The</i> , 2020 , 21, 261-270	21.7	154
401	Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2020 , 82, 101935	14.4	7
400	ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients?. <i>Thrombosis Research</i> , 2020 , 194, 176-177	8.2	4
399	Fasting-mimicking diet and hormone therapy induce breast cancer regression. <i>Nature</i> , 2020 , 583, 620-624	10.4	79
398	Pimasertib Versus Dacarbazine in Patients With Unresectable -Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. <i>Cancers</i> , 2020 , 12,	6.6	12
397	Fasting-mimicking diet plus chemotherapy in breast cancer treatment. <i>Nature Communications</i> , 2020 , 11, 4274	17.4	10
396	Efficacy of Selpercatinib in Fusion-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020 , 383, 813-824	59.2	194
395	Dabrafenib plus trametinib in patients with BRAF-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. <i>Lancet Oncology, The</i> , 2020 , 21, 1234-1243	21.7	120
394	Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). <i>European Journal of Cancer</i> , 2020 , 137, 272-284	7.5	32
393	The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells. <i>Seminars in Cancer Biology</i> , 2020 , 60, 344-350	12.7	10

392	Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 426-435	8.9	96
391	Caring for patients with cancer in the COVID-19 era. <i>Nature Medicine</i> , 2020 , 26, 665-671	50.5	201
390	Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. <i>Breast Cancer Research</i> , 2020 , 22, 33	8.3	14
389	Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials. <i>Oncologist</i> , 2020 , 25, 780-786	5.7	5
388	Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer. <i>Haematologica</i> , 2020 , 105, 1704-1711	6.6	8
387	Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	12
386	Negative Hyperselection of Patients With and Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3099-3110	2.2	35
385	Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma. <i>Tumori</i> , 2019 , 105, 465-473	1.7	2
384	Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. <i>European Urology Oncology</i> , 2019 , 2, 699-707	6.7	19
383	Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?. <i>Pharmacogenomics Journal</i> , 2019 , 19, 465-472	3.5	11
382	Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms. <i>Journal of Pathology: Clinical Research</i> , 2019 , 5, 217-226	5.3	16
381	The role of metastasectomy in advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2019 , 19, 603-611	3.5	7
380	Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1608-1616	2.2	108
379	Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 139, 53-66	7	68
378	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. <i>BMC Cancer</i> , 2019 , 19, 196	4.8	68
377	Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. <i>Scientific Reports</i> , 2019 , 9, 2858	4.9	26
376	Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 116-124	3.8	5
375	Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e179-e190	3.8	7

374	Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. <i>Lung Cancer</i> , 2019 , 132, 72-78	5.9	34
373	Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. <i>ESMO Open</i> , 2019 , 4, e000457	6	93
372	Benefit from anti-EGFRs in and wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. <i>ESMO Open</i> , 2019 , 4, e000489	6	8
371	Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. <i>Lung Cancer</i> , 2019 , 132, 17-23	5.9	11
370	Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies. <i>Cancers</i> , 2019 , 11,	6.6	10
369	Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs. <i>Future Oncology</i> , 2019 , 15, 3015-3024	3.6	0
368	Circulating Tumor DNA Analysis in Colorectal Cancer: From Dream to Reality.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-14	3.6	6
367	Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. <i>Future Oncology</i> , 2019 , 15, 2743-2757	3.6	5
366	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 1268-1275	13.4	37
365	Impact of Metformin on Systemic Metabolism and Survival of Patients With Advanced Pancreatic Neuroendocrine Tumors. <i>Frontiers in Oncology</i> , 2019 , 9, 902	5.3	5
364	The Landscape of Actionable Gene Fusions in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	17
363	Atypical Mutations in Metastatic Colorectal Cancer.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-11	3.6	
362	Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. <i>European Journal of Cancer</i> , 2019 , 107, 164-174	7.5	6
361	Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 34-43.e6	3.8	5
360	Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles. <i>Clinical Breast Cancer</i> , 2019 , 19, e306-e318	3	9
359	Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives. <i>Cancer Treatment Reviews</i> , 2019 , 72, 45-55	14.4	51
358	Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. <i>British Journal of Cancer</i> , 2019 , 120, 165-171	8.7	174
357	Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 237-244	8.9	163

356	Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials. <i>International Journal of Cancer</i> , 2019 , 145, 576-585	7.5	10
355	Exploiting Fasting-mimicking Diet and METformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. <i>Clinical Lung Cancer</i> , 2019 , 20, e413-e417	4.9	15
354	Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 511-521	4.9	107
353	Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). <i>International Journal of Cancer</i> , 2019 , 144, 1704-1712	7.5	9
352	Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world Analysis. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e735-e742	3.3	10
351	Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 123, 57-73	7	26
350	Combination therapies for patients with metastatic renal cell carcinoma. <i>Lancet Oncology, The</i> , 2018 , 19, 281-283	21.7	4
349	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , 2018 , 155, 479-489.e7	13.3	36
348	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018 , 25, 607-618	5.7	13
347	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. <i>British Journal of Cancer</i> , 2018 , 118, 955-965	8.7	10
346	Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies. <i>Pharmacogenomics</i> , 2018 , 19, 1047-1068	2.6	9
345	miR-205 mediates adaptive resistance to MET inhibition via ERFF11 targeting and raised EGFR signaling. <i>EMBO Molecular Medicine</i> , 2018 , 10,	12	17
344	Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. <i>Journal of Clinical Investigation</i> , 2018 , 128, 5505-5516	15.9	120
343	5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer. <i>Oncotarget</i> , 2018 , 9, 16437-16450	3.3	6
342	Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review. <i>Lung Cancer</i> , 2018 , 115, 135-142	5.9	23
341	Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. <i>Clinical Cancer Research</i> , 2018 , 24, 1082-1089	12.9	58
340	CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2836-2844	2.2	296
339	MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review. <i>Frontiers in Oncology</i> , 2018 , 8, 650	5.3	26

338	Immunotherapy-based combinations: an update. <i>Current Opinion in Oncology</i> , 2018 , 30, 345-351	4.2	16
337	Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. <i>Targeted Oncology</i> , 2018 , 13, 795-800	5	14
336	Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. <i>Pharmacogenomics Journal</i> , 2017 , 17, 331-336	3.5	6
335	Complete remission in metastatic breast cancer: expecting the unexpected-results of a cross-sectional study. <i>Breast Cancer</i> , 2017 , 24, 635-641	3.4	3
334	Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors. <i>Future Oncology</i> , 2017 , 13, 1677-1683	3.6	4
333	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. <i>Cancer Medicine</i> , 2017 , 6, 1493-1499	4.8	9
332	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	126
331	MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S393-S394	8.9	18
330	Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. <i>European Journal of Cancer</i> , 2017 , 71, 43-50	7.5	22
329	Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017 , 18, 50-59	4.9	28
328	Evaluation of Local Oncologic Safety in Nipple-Areola Complex-sparing Mastectomy After Primary Chemotherapy: A Propensity Score-matched Study. <i>Clinical Breast Cancer</i> , 2017 , 17, 219-231	3	22
327	Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors. <i>Endocrine</i> , 2017 , 57, 512-517	4	6
326	Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver. <i>European Journal of Surgical Oncology</i> , 2017 , 43, 380-387	3.6	35
325	Uncommon somatic mutations in metastatic NUT midline carcinoma. <i>Tumori</i> , 2017 , 103, e5-e8	1.7	5
324	Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. <i>Journal of Gastrointestinal Oncology</i> , 2017 , 8, 148-163	2.8	54
323	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. <i>ESMO Open</i> , 2017 , 2, e000241	6	6
322	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. <i>Nature</i> , 2017 , 552, 116-120	50.4	290
321	Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. <i>British Journal of Cancer</i> , 2017 , 117, 347-352	8.7	22

320	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 2414-2422	12.9	111
319	Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2017 , 16, e191-e198	3.8	9
318	"Systemic strategy at the patient's service": a congress report on supportive care in oncology. <i>Tumori</i> , 2017 , 0	1.7	
317	IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients. <i>Oncotarget</i> , 2017 , 8, 16887-16898	3.3	24
316	Identification and characterization of a novel rearrangement in a colorectal cancer patient. <i>Oncotarget</i> , 2017 , 8, 55353-55360	3.3	23
315	Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. <i>Cancer Research and Treatment</i> , 2017 , 49, 834-845	5.2	9
314	Multidisciplinary Approach of Prostate Cancer Patients 2017 , 281-293		
313	Whole-exome sequencing in radically resected gastric cancer (GC): Analysis of patients (pts) with poor prognostic factors from the Italian Trial of Adjuvant Chemotherapy Adenocarcinoma (ITACA-S) trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 64-64	2.2	
312	Safety and antitumor activity of weekly carboplatin plus paclitaxel in metastatic breast cancer: A ten years, single-institution, retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e12556-e12556 ²	2.2	0
311	Trends in exposure to multiple lines of treatment and survival of patients with metastatic renal cell carcinoma: A real-world analysis.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16064-e16064	2.2	0
310	Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer: A systematic review and meta-analysis of published trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 98, 24-8	7	16
309	Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. <i>Gastric Cancer</i> , 2016 , 19, 412-420	7.6	25
308	Update on medical treatment of small intestinal neuroendocrine tumors. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 969-76	3.5	4
307	Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. <i>Therapeutic Advances in Medical Oncology</i> , 2016 , 8, 323-30	5.4	10
306	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2016 , 21, 988-94	5.7	72
305	Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors. <i>Tumor Biology</i> , 2016 , 37, 12991-13003	2.9	12
304	Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions. <i>Cancer Discovery</i> , 2016 , 6, 1315-1333	14.3	107
303	miR-9 and miR-200 Regulate PDGFR-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2016 , 76, 5562-72	10.1	67

302	Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials. <i>Breast Cancer Research and Treatment</i> , 2016 , 160, 425-437	4.4	18
301	Trastuzumab cardiac toxicity: a problem we put our heart into. <i>Tumori</i> , 2016 , 102, 1-5	1.7	4
300	Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience. <i>Tumori</i> , 2016 , 102, 501-507	1.7	4
299	Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?. <i>Tumori</i> , 2016 , 102, 18-30	1.7	8
298	The European Cancer Patient's Bill of Rights, update and implementation 2016. <i>ESMO Open</i> , 2016 , 1, e000127	6	25
297	Improved quality of life is the way to longer life. <i>Lancet Oncology, The</i> , 2016 , 17, 862-863	21.7	5
296	Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma. <i>Annals of Oncology</i> , 2016 , 27, 1782-7	10.3	23
295	MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. <i>Cancer Discovery</i> , 2016 , 6, 963-71	24.4	71
294	Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 883-895	21.7	783
293	Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, e81-90	3.3	4
292	GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. <i>Journal of Translational Medicine</i> , 2016 , 14, 125	8.5	26
291	Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016 , 468, 451-61	5.1	2
290	Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. <i>Cancer Discovery</i> , 2016 , 6, 492-500	24.4	245
289	Treatment of elderly patients with metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 323-34	3.5	5
288	Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1017-8	2.2	5
287	Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 100, 99-106	7	11
286	Treatment of lung large cell neuroendocrine carcinoma. <i>Tumor Biology</i> , 2016 , 37, 7047-57	2.9	34
285	An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. <i>Investigational New Drugs</i> , 2016 , 34, 236-42	4.3	20

284	Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. <i>Targeted Oncology</i> , 2016 , 11, 337-43	5	18
283	Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial. <i>Annals of Oncology</i> , 2016 , 27, 668-73	10.3	28
282	Improved health perception after genetic counselling for women at high risk of breast and/or ovarian cancer: construction of new questionnaires--an Italian exploratory study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 633-48	4.9	6
281	Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies. <i>Supportive Care in Cancer</i> , 2016 , 24, 1025-34	3.9	4
280	Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6-6	2.2	28
279	Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. <i>Oncotarget</i> , 2016 , 7, 4428-41	3.3	62
278	Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. <i>Oncotarget</i> , 2016 , 7, 3947-65	3.3	27
277	How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies. <i>Oncotarget</i> , 2016 , 7, 44841-44847	3.3	9
276	Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up. <i>Case Reports in Oncology</i> , 2016 , 9, 432-439	1	2
275	HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature. <i>Breast Care</i> , 2016 , 11, 424-426	2.4	6
274	Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy. <i>Drug Design, Development and Therapy</i> , 2016 , 10, 2167-72	4.4	15
273	Pitfalls in oncology: a unique case of thoracic splenosis mimicking malignancy in a patient with resected breast cancer. <i>Journal of Thoracic Disease</i> , 2016 , 8, E403-7	2.6	1
272	Body mass index and clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer. <i>Tumori</i> , 2016 , 102, e11-4	1.7	11
271	Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. <i>PLoS ONE</i> , 2016 , 11, e0151662	3.7	39
270	Immunotherapy advances in uro-genital malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 105, 52-64	7	16
269	The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. <i>American Journal of Transplantation</i> , 2016 , 16, 2892-2902	8.7	93
268	A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016 , 22, 2146-54	12.9	19
267	Waiting for Godot: Predictive factors for adjuvant treatment of patients with luminal breast cancer. <i>Breast</i> , 2016 , 27, 187-8	3.6	1

266	Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016 , 468, 651-62	5.1	13
265	Diagnosis and management of typical and atypical lung carcinoids. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 100, 167-76	7	26
264	Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study. <i>Thrombosis Research</i> , 2016 , 140 Suppl 1, S55-9	8.2	19
263	Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes. <i>Future Oncology</i> , 2016 , 12, 1251-60	3.6	19
262	HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. <i>International Journal of Cancer</i> , 2016 , 139, 2859-2864	7.5	57
261	Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1590-1598 ^{21.7}	45 ⁰	
260	Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab. <i>International Journal of Cancer</i> , 2015 , 137, 1467-74	7.5	25
259	Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies. <i>Clinical and Translational Oncology</i> , 2015 , 17, 530-8	3.6	2
258	The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer. <i>Cell Adhesion and Migration</i> , 2015 , 9, 14-21	3.2	37
257	In reply. <i>Oncologist</i> , 2015 , 20, e5	5.7	1
256	Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 332.e19-24	2.8	12
255	Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 8884-95	6.3	13
254	Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 95, 272-81	7	13
253	Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review. <i>Future Oncology</i> , 2015 , 11, 1947-59	3.6	9
252	Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies: overall results from a large cohort of patients. <i>Oncology</i> , 2015 , 88, 133-8	3.6	4
251	BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. <i>Annals of Oncology</i> , 2015 , 26, 2092-7	10.3	110
250	Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. <i>Annals of Oncology</i> , 2015 , 26, 1994-1999 ^{18.3}	93	
249	Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis. <i>European Journal of Cancer</i> , 2015 , 51, 800-7	7.5	40

248	Prognosis of women with early breast cancer and PIK3CA mutations. <i>Breast</i> , 2015 , 24, 283-4	3.6	3
247	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015 , 51, 833-40	7.5	60
246	Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2015 , 30, 429-30	3	1
245	DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 581-8	3.8	41
244	Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. <i>Annals of Oncology</i> , 2015 , 26, 657-668	10.3	39
243	Better Together: Targeted Combination Therapies in Breast Cancer. <i>Seminars in Oncology</i> , 2015 , 42, 887-95	3.5	39
242	Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2015 , 7, 152-61	3.2	17
241	Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. <i>Oncologist</i> , 2015 , 20, 1261-5	5.7	29
240	Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 171-7.e1	3.3	8
239	Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 137-41	3.3	16
238	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. <i>Radiotherapy and Oncology</i> , 2015 , 117, 315-21	5.3	24
237	Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3733-40	2.2	159
236	A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors. <i>Annals of Oncology</i> , 2015 , 26, 2341-6	10.3	23
235	Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1319-1327	8.9	112
234	Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors. <i>Annals of Oncology</i> , 2015 , 26, 838-847	10.3	15
233	Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1560-9	8.9	21
232	Challenging Lung Carcinoma with Coexistent Np63/p40 and Thyroid Transcription Factor-1 Labeling Within the Same Individual Tumor Cells. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1500-2	8.9	13
231	HSP1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2015 , 125, 1768-71	2.2	29

230	Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015 , 38, 479-82 ²⁻⁷	25
229	Bevacizumab treatment in the elderly patient with metastatic colorectal cancer. <i>Clinical Interventions in Aging</i> , 2015 , 10, 127-33	4 1
228	Lymphoma Immunotherapy: Current Status. <i>Frontiers in Immunology</i> , 2015 , 6, 448	8.4 32
227	First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 156-66	7 50
226	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2015 , 386, 444-51	40 926
225	Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib. <i>Therapeutic Advances in Urology</i> , 2015 , 7, 59-68	3.2 2
224	Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. <i>Medical Oncology</i> , 2015 , 32, 182	3.7 18
223	BRAF in metastatic colorectal cancer: the future starts now. <i>Pharmacogenomics</i> , 2015 , 16, 2069-81	2.6 13
222	¹⁸ F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015 , 42, 818-30	8.8 29
221	Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. <i>European Journal of Cancer</i> , 2015 , 51, 587-94	7.5 329
220	Phospho-TCTP as a therapeutic target of Dihydroartemisinin for aggressive breast cancer cells. <i>Oncotarget</i> , 2015 , 6, 5275-91	3.3 39
219	A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. <i>Oncotarget</i> , 2015 , 6, 5118-33	3.3 30
218	Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis. <i>Current Drug Targets</i> , 2015 , 16, 164-70	3 36
217	Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders. <i>Cancer Treatment Reviews</i> , 2014 , 40, 197-203	14.4 26
216	PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGF β) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. <i>Investigational New Drugs</i> , 2014 , 32, 555-60	4.3 38
215	Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. <i>New England Journal of Medicine</i> , 2014 , 371, 1877-88	59.2 1195
214	Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?. <i>Journal of Clinical Oncology</i> , 2014 , 32, 859-63	2.2 2
213	Study design and clinical evidence in mRCC: can we save axitinib as a first-line therapy?. <i>Cancer Biology and Therapy</i> , 2014 , 15, 486-8	4.6 2

212	Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. <i>Annals of Oncology</i> , 2014 , 25, 404-8	10.3	51
211	Safety profile and treatment response of everolimus in different solid tumors: an observational study. <i>Future Oncology</i> , 2014 , 10, 1611-7	3.6	8
210	Clinical outcome of HER2-positive breast cancer patients after failure on adjuvant trastuzumab: the potential of the time to relapse. <i>Clinical Oncology</i> , 2014 , 26, 174	2.8	1
209	Targeting the MET gene for the treatment of non-small-cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 89, 284-99	7	61
208	Predictive testing for DPD deficiency in a patient with familial history of fluoropyrimidine-associated toxicity. <i>Personalized Medicine</i> , 2014 , 11, 259-262	2.2	4
207	Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. <i>PLoS ONE</i> , 2014 , 9, e92147	3.7	17
206	Targeted treatments in advanced renal cell carcinoma: focus on axitinib. <i>Pharmacogenomics and Personalized Medicine</i> , 2014 , 7, 107-16	2.1	5
205	Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. <i>British Journal of Cancer</i> , 2014 , 110, 26-33	8.7	16
204	First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profile. <i>Cancer Biology and Therapy</i> , 2014 , 15, 19-21	4.6	5
203	Real-world study of everolimus in advanced progressive neuroendocrine tumors. <i>Oncologist</i> , 2014 , 19, 966-74	5.7	66
202	A catalyst for change: the European cancer Patient's Bill of Rights. <i>Oncologist</i> , 2014 , 19, 217-24	5.7	24
201	Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens. <i>Cancers</i> , 2014 , 6, 1753-68	6.6	13
200	FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. <i>Oncologist</i> , 2014 , 19, 845-50	5.7	37
199	TP53 mutations in advanced colorectal cancer: the dark side of the moon. <i>Oncology</i> , 2014 , 86, 289-94	3.6	8
198	Phase Ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets. <i>Oncologist</i> , 2014 , 19, 344-5	5.7	6
197	Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. <i>Annals of Oncology</i> , 2014 , 25, 2244-2251	10.3	133
196	Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. <i>Annals of Oncology</i> , 2014 , 25, 1597-603	10.3	45
195	FOLFIRI with cetuximab or bevacizumab: FIRE-3. <i>Lancet Oncology</i> , 2014 , 15, e581	21.7	1

194	Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. <i>British Journal of Clinical Pharmacology</i> , 2014 , 78, 1228-37	3.8	32
193	Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases. <i>International Journal of Surgical Pathology</i> , 2014 , 22, 136-48	1.2	6
192	Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. <i>Future Oncology</i> , 2014 , 10, 1361-72	3.6	6
191	Aprepitant versus dexamethasone for delayed emesis: what is the role of the 5-hydroxytryptamine type 3 receptor antagonist palonosetron?. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2185-6	2.2	3
190	Butterfly and renal cell cancer: out of chaos comes order. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3083	2.2	2
189	Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies. <i>PLoS ONE</i> , 2014 , 9, e108940	3.7	46
188	Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 203-209.e1	3.3	14
187	Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 223-30	8.8	72
186	Role of MGMT as biomarker in colorectal cancer. <i>World Journal of Clinical Cases</i> , 2014 , 2, 835-9	1.6	21
185	Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors. <i>Tumori</i> , 2014 , 100, e286-9	1.7	13
184	Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. <i>Oncotarget</i> , 2014 , 5, 2839-52	3.3	134
183	Rationale and Protocol of SOAP: A Phase II Study to Evaluate the Efficacy of Sorafenib as Second-Line Treatment after Pazopanib in Patients with Advanced Renal Cell Carcinoma. <i>Tumori</i> , 2014 , 100, e282-e285	1.7	
182	Role of BAX for outcome prediction in gastrointestinal malignancies. <i>Medical Oncology</i> , 2013 , 30, 610	3.7	7
181	Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients. <i>Clinical and Translational Oncology</i> , 2013 , 15, 582-6	3.6	2
180	Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013 , 139, 447-55	4.9	70
179	Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. <i>Nature Genetics</i> , 2013 , 45, 1470-1473	36.3	464
178	A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. <i>European Journal of Cancer</i> , 2013 , 49, 290-6	7.5	66
177	Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 484-8	3.3	34

176	Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?. <i>Oncology</i> , 2013 , 84, 191-9	3.6	27
175	Palonosetron plus dexamethasone in highly emetogenic chemotherapy: pooled data from two Phase III trials. <i>Future Oncology</i> , 2013 , 9, 1451-8	3.6	5
174	Patient approach in advanced/metastatic renal cell carcinoma: focus on the elderly population and treatment-related toxicity. <i>Future Oncology</i> , 2013 , 9, 1599-607	3.6	6
173	Pancreatic well-differentiated neuroendocrine neoplasms (pWDNENs): what place for everolimus and sunitinib derived from ESMO clinical practice guidelines in the therapeutic algorithm?. <i>Annals of Oncology</i> , 2013 , 24, 1415-6	10.3	2
172	To target or not to target, that is the question. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1254	2.2	2
171	Role of cMET in the development and progression of colorectal cancer. <i>International Journal of Molecular Sciences</i> , 2013 , 14, 18056-77	6.3	38
170	Biological insights into BRAF mutations in melanoma patient: Not mere therapeutic targets. <i>Oncolmmunology</i> , 2013 , 2, e25594	7.2	4
169	p63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization. <i>International Journal of Surgical Pathology</i> , 2013 , 21, 229-39	1.2	46
168	Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy. <i>Cancer Biology and Therapy</i> , 2013 , 14, 1098-103	4.6	22
167	Is a dexamethasone-sparing strategy capable of preventing acute and delayed emesis caused by combined doxorubicin and paclitaxel for breast cancer? Analysis of a phase II trial. <i>Oncology</i> , 2013 , 84, 371-7	3.6	3
166	Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting. <i>Patient Preference and Adherence</i> , 2013 , 7, 391-400	2.4	15
165	Well-differentiated neuroendocrine tumor of tailgut cyst. A rare entity with controversial medical opportunities. <i>Tumori</i> , 2013 , 99, e148-51	1.7	4
164	Update on Therapeutic Strategy in Lung Carcinoids. <i>Journal of Cancer Therapy</i> , 2013 , 04, 1466-1471	0.2	1
163	A review on biomarkers for prediction of treatment outcome in gastric cancer. <i>Anticancer Research</i> , 2013 , 33, 1257-66	2.3	48
162	Re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. <i>Eur Urol</i> 2012;61:826-33. <i>European Urology</i> , 2012 , 62, e5-6; author reply e7-8	10.2	1
161	Bax expression is predictive of favorable clinical outcome in chemo-naïve advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen. <i>Translational Oncology</i> , 2012 , 5, 155-9	4.9	13
160	Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors. <i>Neuroendocrinology</i> , 2012 , 96, 32-40	5.6	44
159	Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. <i>Lancet Oncology</i> , 2012 , 13, 810-6	21.7	119

158	Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 83, 432-43	7	24
157	Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. <i>Lung Cancer</i> , 2012 , 77, 507-14	5.9	54
156	Adjuvant treatment of colorectal cancer in the elderly: Where do we come from and where are we going?. <i>Journal of Solid Tumors</i> , 2012 , 2,	0.3	1
155	Succinate dehydrogenase B subunit immunohistochemical expression predicts aggressiveness in well differentiated neuroendocrine tumors of the ileum. <i>Cancers</i> , 2012 , 4, 808-20	6.6	4
154	Experience with sorafenib in the treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2012 , 4, 303-13	3.2	14
153	Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies. <i>British Journal of Cancer</i> , 2012 , 107, 1227-32	8.7	18
152	Tackling off-label use of anticancer drugs. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2800; author reply 2801-2	3	
151	Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306. <i>Annals of Oncology</i> , 2012 , 23, 2771-2772	10.3	1
150	Features and prognostic factors of large node-negative non-small-cell lung cancers shifted to stage II. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1124-30	8.9	1
149	Pharmacokinetic (PK) and pharmacodynamic (PD) analysis from a phase I study of PF-03446962, a fully human mAb against ALK1, a TGF-beta receptor involved in tumor angiogenesis.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e13606-e13606	2.2	1
148	Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 388-388	2.2	6
147	New perspectives in advanced genitourinary malignancies. <i>Tumori</i> , 2012 , 98, 267-9	1.7	1
146	Pharmacokinetic modeling and simulation (PK M&S) supported dose escalation of PF-03446962, a monoclonal antibody (mAb) against activin receptor like kinase 1, in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2595-2595	2.2	
145	Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. <i>Tumori</i> , 2012 , 98, 279-86	1.7	4
144	Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 768-73	8.9	5
143	Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. <i>British Journal of Cancer</i> , 2011 , 104, 1686-90	8.7	56
142	"Waiting and the waiting room: how do you experience them?" emotional implications and suggestions from patients with cancer. <i>Journal of Cancer Education</i> , 2011 , 26, 388-94	1.8	17
141	Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. <i>Annals of Oncology</i> , 2011 , 22, 1535-1546	10.3	572

140	Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination. <i>Chemotherapy</i> , 2011 , 57, 217-24	3.2	4
139	Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2372-7	2.2	216
138	Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors. <i>Clinical Cancer Research</i> , 2011 , 17, 1964-72	12.9	47
137	Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1895-901	8.9	96
136	Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1465-71	2.2	526
135	A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. <i>Annals of Oncology</i> , 2011 , 22, 1413-1419	10.3	63
134	A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. <i>Clinical Cancer Research</i> , 2011 , 17, 7732-42	12.9	116
133	Neuroendocrine tumour arising inside a retro-rectal tailgut cyst: report of two cases and a review of the literature. <i>Ecancermedalscience</i> , 2011 , 5, 201	2.7	17
132	Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2010 , 103, 837-44	8.7	26
131	Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2604-11	2.2	101
130	Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer. <i>Pharmacogenomics Journal</i> , 2010 , 10, 180-90	3.5	16
129	Oncolytic adenovirus treatment of a patient with refractory neuroblastoma. <i>Acta Oncologica</i> , 2010 , 49, 117-9	3.2	30
128	The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2010 , 46, 2926-35	7.5	125
127	Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. <i>Cancer Treatment Reviews</i> , 2010 , 36 Suppl 3, S87-94	14.4	31
126	A critical appraisal of the adjuvant chemotherapy guidelines for patients with completely resected T3N0 non-small-cell lung cancer. <i>Acta Oncologica</i> , 2010 , 49, 480-4	3.2	12
125	Adjuvant chemotherapy in new stage II pN0 non-small cell lung cancer: a new issue for a case-by-case decision making process. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 754	8.9	1
124	Colon cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2010 , 74, 106-33	7	172
123	Off-Label Prescription of Antineoplastic Drugs: An Italian Prospective, Observational, Multicenter Survey. <i>Tumori</i> , 2009 , 95, 647-651	1.7	13

122	Right pelvic mass in a patient with a radically resected carcinoid of the appendix. <i>Gut</i> , 2009 , 58, 1200, 1259	19.2	
121	Health-related quality of life in patients with hormone refractory prostate cancer receiving gefitinib. <i>Urologia Internationalis</i> , 2009 , 82, 196-202	1.9	3
120	Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer. <i>Annals of Oncology</i> , 2009 , 20, 498-502	10.3	8
119	Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents. <i>Oncology</i> , 2009 , 77, 358-65	3.6	8
118	Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial. <i>Annals of Oncology</i> , 2009 , 20, 935-40	10.3	157
117	QTc prolongation assessment in anticancer drug development: clinical and methodological issues. <i>Ecancermedicalscience</i> , 2009 , 3, 130	2.7	8
116	Gemcitabine and pemetrexed combination: the key role of the sequence of drugs administration. <i>Annals of Oncology</i> , 2009 , 20, 1747-8	10.3	1
115	Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 301-6	3.5	9
114	Rectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 70, 160-82	7	12
113	Gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 71, 127-64	7	316
112	Molecular target therapy for gastroenteropancreatic endocrine tumours: biological rationale and clinical perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 72, 110-24	7	32
111	Capecitabine initially concomitant to radiotherapy then perioperatively administered in locally advanced rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 75, 421-7	4	30
110	Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 663-71	2.2	1360
109	Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. <i>European Journal of Cancer</i> , 2009 , 45, 1153-1161	7.5	47
108	Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. <i>European Journal of Cancer</i> , 2009 , 45, 2116-22	7.5	30
107	Erlotinib combined with cyclosporine in a liver-transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 138-9	8.9	4
106	Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. <i>European Journal of Cancer</i> , 2008 , 44, 494-500	7.5	35
105	Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5407-15	2.2	198

104	Miliary hepatic metastases from neuroendocrine carcinoma. <i>Digestive Surgery</i> , 2008 , 25, 330	2.5	6
103	Participation in clinical trials as viewed by the patient: understanding cultural and emotional aspects which influence choice. <i>Oncology</i> , 2008 , 74, 177-87	3.6	41
102	Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. <i>Annals of Oncology</i> , 2008 , 19, 173-7	10.3	51
101	Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura. <i>Journal of Thoracic Oncology</i> , 2008 , 3, 938-41	8.9	41
100	Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib?. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 63, 139-48	3.5	10
99	Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: a survey from the Italian National Monitoring Centre for Clinical Trials. <i>Trials</i> , 2008 , 9, 46	2.8	3
98	Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five cases. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 65, 1-7	7	76
97	A 15-min premedication for 1-h paclitaxel infusion: optimizing patients' care. <i>Lung Cancer</i> , 2007 , 58, 300-4	3.9	2
96	First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. <i>Cancer</i> , 2007 , 110, 752-8	6.4	35
95	Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib. <i>Prostate</i> , 2007 , 67, 603-4	4.2	16
94	Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. <i>Endocrine-Related Cancer</i> , 2007 , 14, 473-82	5.7	110
93	Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. <i>Journal of Clinical Oncology</i> , 2007 , 25, 102-9	2.2	196
92	Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?. <i>Annals of Oncology</i> , 2007 , 18, 13-19	10.3	70
91	Re: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 1345-6; author reply 1346-7	9.7	4
90	Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3217-23	2.2	219
89	Adjuvant Surgery after Carboplatin and VP16 in Resectable Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 131-134	8.9	10
88	Oligometastatic non-small cell lung cancer: a multidisciplinary approach in the positron emission tomographic scan era. <i>Annals of Thoracic Surgery</i> , 2007 , 83, 231-4	2.7	23
87	Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity. <i>Anti-Cancer Drugs</i> , 2007 , 18, 949-54	2.4	8

86	Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study. <i>Cancer</i> , 2006 , 107, 2474-81	6.4	59
85	Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy. <i>Annals of Oncology</i> , 2006 , 17, 1174-5	10.3	12
84	Successful chemotherapy and 90Y-DOTATOC in a patient with mediastinal highly aggressive neuroendocrine carcinoma. <i>Acta Oncologica</i> , 2006 , 45, 627-9	3.2	6
83	"Burned out" phenomenon of the testis in retroperitoneal seminoma. <i>Acta Oncologica</i> , 2006 , 45, 335-6	3.2	13
82	Reply to Letter to the Editor: "Toxic epidermal necrolysis in patients with malignancies" by G. Gravante, G. Esposito, M. Marianetti, D. Delogu, G. Sconocchia & A. Montone (doi:10.1093/annonc/mdl089). <i>Annals of Oncology</i> , 2006 , 17, 1601-1602	10.3	0
81	Factor v leiden mutation in patients with breast cancer with a central venous catheter: risk of deep vein thrombosis. <i>Supportive Cancer Therapy</i> , 2006 , 3, 98-102		11
80	A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients. <i>Lung Cancer</i> , 2006 , 54, 359-64	5.9	4
79	Breast cancer vaccines: a clinical reality or fairy tale?. <i>Annals of Oncology</i> , 2006 , 17, 750-62	10.3	61
78	In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. <i>British Journal of Cancer</i> , 2006 , 95, 289-97	8.7	37
77	Pharmacogenetics in Oncology 2006 , 129-153		
76	Extended pneumonectomy with partial resection of the left atrium, without cardiopulmonary bypass, for lung cancer. <i>Annals of Thoracic Surgery</i> , 2005 , 79, 234-40	2.7	64
75	Tumour CEA as predictor of better outcome in squamous cell carcinoma of the lung. <i>Lung Cancer</i> , 2005 , 48, 233-40	5.9	16
74	Gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2005 , 54, 209-41	7	65
73	Three-times-daily radiotherapy with induction chemotherapy in locally advanced non-small cell lung cancer. Feasibility and toxicity study. <i>Strahlentherapie Und Onkologie</i> , 2005 , 181, 363-71	4.3	17
72	Cancer of the prostate. <i>Critical Reviews in Oncology/Hematology</i> , 2005 , 56, 379-96	7	78
71	Oral administration of vinorelbine can overcome intractable endovenous-vinorelbine-associated acute tumor pain. <i>Supportive Care in Cancer</i> , 2005 , 13, 194-5	3.9	6
70	Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery. <i>Breast Cancer Research and Treatment</i> , 2005 , 93, 35-40	4.4	53
69	Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 461-2; author reply 462-3	9.7	3

68	Target-treatment and patients' selection: can we still neglect the timing of tissue collection?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6274-5; author reply 6275-6	2.2	2
67	Prophylaxis for venous thromboembolism in cancer patients with a central vein catheter: new tones for an old song. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7243-4; author reply 7244	2.2	3
66	Immunohistochemical detection of HER1/HER2 can be considered a predictive marker of gefitinib activity in non-small-cell lung cancer?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 921-2; author reply 922	2.2	4
65	Anti-inflammatory properties of the novel antitumor agent yonnelis (trabectedin): inhibition of macrophage differentiation and cytokine production. <i>Cancer Research</i> , 2005 , 65, 2964-71	10.1	234
64	Reply to the article "Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity" by V. R. Rozados et al. (Ann Oncol 2004; 15: 1543-1550): ... and in humans?. <i>Annals of Oncology</i> , 2005 , 16, 673	10.3	6
63	Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1867-74	2.2	148
62	Drug-induced prolongation of the QT interval. <i>New England Journal of Medicine</i> , 2004 , 350, 2618-21; author reply 2618-21	59.2	14
61	CDX-2 should be included in the work-up of patients with lung metastases from unknown primary. <i>Annals of Oncology</i> , 2004 , 15, 1850	10.3	1
60	Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4966-70	2.2	30
59	5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial. <i>Annals of Oncology</i> , 2004 , 15, 759-64	10.3	38
58	Colon cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2004 , 51, 145-70	7	27
57	Hyperfractionated radiotherapy in locally advanced nasopharyngeal cancer. An analysis of 43 consecutive patients. <i>Strahlentherapie Und Onkologie</i> , 2004 , 180, 425-33	4.3	12
56	Cancer of pancreas. <i>Critical Reviews in Oncology/Hematology</i> , 2004 , 50, 147-55	7	16
55	Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patients. <i>Cancer</i> , 2004 , 101, 1302-10	6.4	151
54	Rectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2004 , 51, 121-43	7	8
53	Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine features. <i>Clinical Breast Cancer</i> , 2004 , 5, 125-30	3	15
52	Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma. <i>European Journal of Cancer</i> , 2004 , 40, 1872-7	7.5	115
51	Respiratory function changes after chemotherapy: an additional risk for postoperative respiratory complications?. <i>Annals of Thoracic Surgery</i> , 2004 , 77, 260-5; discussion 265	2.7	87

50	Imatinib administration in two patients with liver metastases from GIST and severe jaundice. <i>British Journal of Cancer</i> , 2003 , 89, 1403-4	8.7	5
49	Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2003 , 44 Suppl 3, S115-22	1.9	7
48	Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas?. <i>Oncology</i> , 2003 , 64, 186-8	3.6	14
47	Preoperative chemotherapy is essential for conservative surgery of Askin tumors. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2003 , 125, 428-9	1.5	19
46	Malignant melanoma. <i>Critical Reviews in Oncology/Hematology</i> , 2003 , 47, 35-63	7	50
45	Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group. <i>British Journal of Cancer</i> , 2003 , 88, 645-7	8.7	9
44	Lessons from the ("Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations. <i>British Journal of Cancer</i> , 2003 , 89 Suppl 2, S19-23	8.7	20
43	Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. <i>Pharmacological Reviews</i> , 2003 , 55, 57-103	22.5	58
42	Preoperative chemotherapy in non-small-cell lung cancer: nothing new in N2 disease. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2603-4; author reply 2605	2.2	1
41	Phase II trial of vinorelbine, cisplatin and continuous infusion of 5-fluorouracil followed by hyperfractionated radiotherapy in locally advanced head and neck cancer. <i>Oncology</i> , 2002 , 63, 115-23	3.6	5
40	Bladder cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2002 , 41, 89-106	7	24
39	Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. <i>Annals of Oncology</i> , 2002 , 13, 73-80	10.3	373
38	Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. <i>Annals of Oncology</i> , 2002 , 13, 895-902	10.3	29
37	Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas. <i>Annals of Oncology</i> , 2002 , 13, 161-6	10.3	15
36	A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients. <i>Cancer</i> , 2001 , 92, 1204-12	6.4	114
35	Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients. <i>Biopharmaceutics and Drug Disposition</i> , 2001 , 22, 191-7	1.7	66
34	Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001 , 28, 426-34		167
33	Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine. <i>Lung Cancer</i> , 2001 , 31, 267-70	5.9	17

32	Pharmacogenetic determinants of anti-cancer drug activity and toxicity. <i>Trends in Pharmacological Sciences</i> , 2001 , 22, 420-6	13.2	52
31	Is there a Real Advantage in Utilizing Central Venous Ports in Oncology Surgery? An Analysis of the Cost-Effectiveness Ratio. <i>Tumori</i> , 2001 , 87, 74-75	1.7	3
30	Gemcitabine-induced systemic capillary leak syndrome. <i>Annals of Oncology</i> , 2001 , 12, 1651-2	10.3	34
29	Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , 2001 , 12, 1553-9	10.3	29
28	Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2000 , 11, 821-7	10.3	25
27	Ifosfamide in the elderly: clinical considerations for a better drug management. <i>Critical Reviews in Oncology/Hematology</i> , 2000 , 33, 129-35	7	9
26	Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): is prophylaxis required?. <i>Annals of Oncology</i> , 2000 , 11, 117-8	10.3	8
25	Very low acute toxicity of three fractions per day accelerated radiotherapy given after induction chemotherapy and surgery in stage III non-small cell lung cancer. <i>Lung Cancer</i> , 2000 , 30, 149-50	5.9	2
24	Pharmacokinetics of Oral Doxifluridine in Patients with Colorectal Cancer. <i>Tumori</i> , 1999 , 85, 47-50	1.7	3
23	Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999 , 26, 348-57	8.8	150
22	START: a European state-of-the-art on-line instrument for clinical oncologists. <i>Annals of Oncology</i> , 1999 , 10, 769-73	10.3	12
21	Primary chemotherapy in operable breast cancer with favorable prognostic factors: a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN). <i>Annals of Oncology</i> , 1999 , 10, 993-6	10.3	20
20	Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program. <i>Annals of Oncology</i> , 1999 , 10, 1311-6	10.3	42
19	Induction chemotherapy followed by simultaneous hyperfractionated radiochemotherapy in advanced head and neck cancer. A pilot study. <i>Strahlentherapie Und Onkologie</i> , 1998 , 174, 457-61	4.3	4
18	Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998 , 25, 1336-9	8.8	27
17	Practical considerations in the treatment of hepatocellular carcinoma. <i>Drugs</i> , 1998 , 55, 367-82	12.1	18
16	Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. <i>Annals of Oncology</i> , 1998 , 9, 105-8	10.3	185
15	Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. <i>Annals of Oncology</i> , 1998 , 9, 767-73	10.3	206

14	High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible?. <i>Annals of Oncology</i> , 1998 , 9, 917-9	10.3	31
13	Activity and Tolerability of Courses of Intra-Arterial Chemotherapy Followed by Chemoembolization in Unresectable Hepatocellular Carcinoma. <i>Tumori</i> , 1998 , 84, 673-676	1.7	2
12	Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998 , 21, 279-83	2.7	34
11	Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden. <i>Annals of Oncology</i> , 1997 , 8, 865-70	10.3	27
10	Long-term, totally implantable central venous access ports connected to a Groshong catheter for chemotherapy of solid tumours: experience from 178 cases using a single type of device. <i>European Journal of Cancer</i> , 1997 , 33, 1190-4	7.5	92
9	Phase II study of the etoposide, leucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy. <i>Oncology</i> , 1995 , 52, 41-4	3.6	19
8	Tumor vascularization, mitotic index, histopathologic grade, and DNA ploidy in the assessment of 114 head and neck squamous cell carcinomas. <i>Cancer</i> , 1995 , 75, 1649-56	6.4	62
7	Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (I.T.M.O.) Group. <i>European Journal of Cancer</i> , 1994 , 30A, 596-600	7.5	12
6	Treatment of carcinoid syndrome with recombinant interferon alpha-2a. <i>Acta Oncologica</i> , 1993 , 32, 235-8	3.2	33
5	Salvage treatment after r-interferon alpha-2a in advanced neuroendocrine tumors. <i>Acta Oncologica</i> , 1993 , 32, 245-50	3.2	17
4	Adjuvant Chemotherapy for Cancer of Gastrointestinal Tract: A Critical Review. <i>Tumori</i> , 1992 , 78, 228-234	1.7	2
3	Expression of the T1 (CD5, p67) surface antigen in B-CLL and B-NHL and its correlation with other B-cell differentiation markers. <i>Hematological Oncology</i> , 1986 , 4, 237-48	1.3	15
2	Characterization of the response of human thymocytes and blood lymphocytes to the synergistic mitogenicity of 12-O-tetradecanoylphorbol-13-acetate (TPA)-ionomycin. <i>European Journal of Immunology</i> , 1984 , 14, 720-4	6.1	30
1	Pazopanib induces dramatic but transient contraction of myeloid suppression compartment in favor of adaptive immunity		1